US FDA review officials believe the experience with post-marketing cardiovascular outcomes trials in diabetes is a strong indication that it will be possible to complete rigorous, long-term confirmatory studies for drugs that receive Accelerated Approval to treat NASH.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?